Profile data is unavailable for this security.
About the company
Getein Biotech Inc is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. Its in vitro diagnostic reagents include Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, hemagglutination reagents and others. Its diagnostic instruments include immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000 and five classification blood cell analyzer BHA-5000, among others. The Company also provides testing and agency services. The Company distributes its products within domestic market and to overseas markets.
- Revenue in CNY (TTM)1.31bn
- Net income in CNY244.26m
- Incorporated2002
- Employees2.14k
- LocationGetein Biotech IncNo. 9, Bofu Road, Yanjiang IndustrialDevelopment Zone, Liuhe DistrictNANJING 211505ChinaCHN
- Phone+86 2 568568577
- Fax+86 2 568568577
- Websitehttps://www.getein.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Medicilon Inc | 1.17bn | -172.33m | 4.44bn | 2.60k | -- | 1.80 | -- | 3.78 | -1.24 | -1.24 | 9.11 | 18.34 | 0.4205 | 6.63 | 1.64 | 451,437.20 | -6.17 | 9.34 | -7.97 | 11.73 | 12.48 | 36.71 | -14.68 | 14.93 | 2.63 | -- | 0.1229 | 20.18 | -17.68 | 33.26 | -109.82 | -- | 23.60 | -- |
| Hainan Huluwa Pharmaceutical Grop Co Ltd | 1.81bn | 94.97m | 4.46bn | 2.47k | 46.93 | 3.88 | -- | 2.46 | 0.2374 | 0.2374 | 4.52 | 2.87 | 0.6721 | 2.88 | 3.81 | 732,708.90 | 3.80 | 5.81 | 6.29 | 9.78 | 50.33 | 58.01 | 5.66 | 7.03 | 0.8245 | 7.04 | 0.5246 | 21.74 | 25.75 | 14.13 | 24.29 | 1.16 | 46.37 | -- |
| Shanghai Haoyuan Chemexpress Co Ltd | 1.97bn | 97.97m | 4.53bn | 3.37k | 46.16 | 1.78 | -- | 2.30 | 0.652 | 0.652 | 13.10 | 16.92 | 0.4845 | 1.01 | 3.91 | 583,547.80 | 2.38 | 7.38 | 3.23 | 9.60 | 42.51 | 47.03 | 4.92 | 13.53 | 0.894 | 3.37 | 0.3013 | 14.37 | 38.44 | 44.33 | -34.18 | 47.24 | 48.95 | -- |
| Beijing Konruns Pharmaceutical Co Ltd | 954.14m | 166.44m | 4.53bn | 447.00 | 26.72 | 1.43 | -- | 4.75 | 1.06 | 1.06 | 6.05 | 19.78 | 0.2548 | 2.50 | 3.73 | 2,134,547.00 | 5.46 | 5.43 | 6.39 | 6.24 | 88.29 | 89.93 | 21.44 | 20.76 | 3.08 | -- | 0.0486 | 21.53 | 6.15 | -2.08 | 48.24 | -10.63 | 43.05 | -9.71 |
| Getein Biotech Inc | 1.31bn | 244.26m | 4.57bn | 2.14k | 18.73 | 1.73 | -- | 3.50 | 0.4816 | 0.4816 | 2.58 | 5.22 | 0.3502 | 1.61 | 2.77 | 611,337.70 | 6.63 | 13.25 | 9.24 | 18.45 | 66.13 | 65.57 | 18.92 | 28.13 | 1.97 | -- | 0.1857 | 29.88 | -24.85 | 14.81 | -43.92 | 2.31 | 18.44 | 6.00 |
| Hangzhou Alltest Biotech Co Ltd | 718.48m | 184.83m | 4.58bn | 1.09k | 24.80 | 1.17 | -- | 6.37 | 2.33 | 2.33 | 9.02 | 49.43 | 0.165 | 2.13 | 6.17 | 657,349.00 | 4.24 | 23.35 | 4.57 | 26.83 | 46.83 | 58.34 | 25.69 | 39.07 | 10.16 | -- | 0.0056 | 29.79 | -77.73 | 32.59 | -84.75 | 26.19 | 72.77 | -- |
| Beijing Kawin Technol Sha-hld Co Ltd | 1.43bn | 117.53m | 4.67bn | 584.00 | 38.65 | 2.57 | -- | 3.26 | 0.7061 | 0.7061 | 8.61 | 10.60 | 0.6264 | 1.66 | 4.42 | 2,451,945.00 | 6.11 | 5.31 | 7.69 | 6.76 | 82.35 | 86.02 | 9.76 | 8.10 | 3.25 | -- | 0.0809 | 43.82 | 21.73 | 14.87 | 39.71 | 21.04 | 25.01 | -- |
| Shanghai Haixin Group Co Ltd | 1.11bn | 171.70m | 4.67bn | 760.00 | 37.97 | 1.65 | -- | 4.21 | 0.1422 | 0.1422 | 0.9185 | 3.27 | 0.2246 | 7.19 | 9.32 | 1,458,849.00 | 4.05 | 2.68 | 4.57 | 3.06 | 46.37 | 44.55 | 18.02 | 11.17 | 2.83 | -- | 0.0089 | 36.10 | -17.88 | 1.48 | 1.20 | 4.19 | -10.27 | 13.18 |
Data as of May 31 2024. Currency figures normalised to Getein Biotech Inc's reporting currency: Chinese Yuan Renminbi CNY
1.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 3.99m | 0.79% |
| Maxwealth Fund Management Co., Ltd.as of 31 Dec 2023 | 1.01m | 0.20% |
| Wanjia Asset Management Co., Ltd.as of 31 Dec 2023 | 864.45k | 0.17% |
| Gfund Management Co., Ltd.as of 31 Dec 2023 | 771.01k | 0.15% |
| Truvalue Asset Management Co. Ltd.as of 31 Dec 2023 | 745.85k | 0.15% |
| Morgan Stanley Huaxin Fund Management Co., Ltd.as of 31 Dec 2023 | 668.90k | 0.13% |
| SSgA Funds Management, Inc.as of 09 May 2024 | 629.48k | 0.12% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 532.79k | 0.11% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 484.58k | 0.10% |
| Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 390.80k | 0.08% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
